PPARA and type 2 diabetes mellitus: Although aleglitazar’s development was recently halted due to lack of efficacy in CV outcomes indicating no CV benefit, and PPAR-related class side effects in the post-ACS T2D population [12], the renal effects of dual PPAR-α/γ activation remain of interest—in particular, the development of another PPAR-α/γ agonist, tesaglitazar—was terminated over concerns about the degree and potential lack of reversibility of elevations in SCr.